2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma
A Anghelone, A Strusi, A Scala… - Expert Review of …, 2023 - Taylor & Francis
This article describes the main acquisitions of renal cell carcinoma (RCC) management
presented during the 2023 American Society of Clinical Oncology (ASCO) Genitourinary …
presented during the 2023 American Society of Clinical Oncology (ASCO) Genitourinary …
[HTML][HTML] Active Surveillance in Metastatic Renal Cell Carcinoma
N Beecroft, TD Gauntner, R Upadhyay… - Journal of Kidney …, 2024 - ncbi.nlm.nih.gov
Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with a variable clinical
course. While therapies for treatment of this condition have progressed, they are not without …
course. While therapies for treatment of this condition have progressed, they are not without …
PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma
JS Park, ME Lee, J Kim, K Oh, N Lee, M Jung… - Cancer Cell …, 2024 - Springer
Background Although a combination of immune checkpoint inhibitors (ICIs) is recommended
as the first line treatment option for metastatic renal cell carcinoma (mRCC), several immune …
as the first line treatment option for metastatic renal cell carcinoma (mRCC), several immune …
[HTML][HTML] Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus …
CM Mantia, OA Jegede, ER Plimack… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Background Immunotherapy can be associated with prolonged disease control even after
cessation of treatment without the need for further cancer-directed therapy. Treatment …
cessation of treatment without the need for further cancer-directed therapy. Treatment …
[HTML][HTML] KIDNEY CANCER
N Beecroft, TD Gauntner, R Upadhyay, SJ Wang… - jkcvhl.com
Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with a variable clinical
course. While therapies for treatment of this condition have progressed, they are not without …
course. While therapies for treatment of this condition have progressed, they are not without …
[HTML][HTML] Considering Disease Risk Criteria When Choosing Systemic Therapy for Advanced RCC
A Sternberg - 2023 - targetedonc.com
Combination therapies for patients with advanced renal cell carcinoma provides clinicians
with new treatment avenues for their patients. To assess which path to go down, Tian Zhang …
with new treatment avenues for their patients. To assess which path to go down, Tian Zhang …